
UP-TO-DATE, RESEARCH BASED INFORMATION ABOUT PSYCHEDELICS.
Trauma under psychedelics: MDMA shows protective effects during the peritraumatic period
These novel findings suggest that the influence of MDMA during the TE may carry protective effects into the peritraumatic period, possibly mediated through the known effects of MDMA in reducing negative emotions and elevating prosociality. These protective effects in turn may mitigate the development of early psychopathology-related symptoms.
Magnesium–ibogaine therapy in veterans with traumatic brain injuries
In the present study, we report a prospective observational study of the Magnesium–Ibogaine: the Stanford Traumatic Injury to the CNS protocol (MISTIC), provided together with complementary treatment modalities, in 30 male SOVs with predominantly mild TBI.
Treating posttraumatic stress disorder and alcohol use disorder comorbidity: Current pharmacological therapies and the future of MDMA-integrated psychotherapy
The following reviews the current research for clinical pharmacotherapies, as well as MDMA-integrative psychotherapy as they pertain to PTSD and AUD in isolation and co-occurrence. Future directions for the role of psychedelic-integrative therapy for the treatment of this comorbidity are discussed.
Hallucinogenic drugs and their potential for treating fear-related disorders: Through the lens of fear extinction
This paper provides the first comprehensive review of hallucinogens' potential to alleviate symptoms of fear-related disorders
YouGov results - Is the UK ready to reschedule psilocybin?
UK survey on attitudes to psilocybin
A randomized controlled trial of repeated ketamine administration for chronic posttraumatic stress disorder
ketamine administration for chronic posttraumatic stress disorder
Pharmacological-assisted Psychotherapy for Post-Traumatic Stress Disorder: a systematic review and meta-analysis.
Pharmacological-assisted Psychotherapy for Post-Traumatic Stress Disorder
MAPS report successful outcome of their first phase 3 trial of MDMA-assisted therapy for PTSD
MAPS completes successful phase 3 study of MDMA for PTSD